Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride.

[1]  R. Morgan-Warren,et al.  A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension , 2012, Clinical ophthalmology.

[2]  P. Caron,et al.  Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats: a protective effect of a myosin light chain kinase inhibitor. , 2013, Investigative ophthalmology & visual science.

[3]  I. Fournier,et al.  A New Safety Concern for Glaucoma Treatment Demonstrated by Mass Spectrometry Imaging of Benzalkonium Chloride Distribution in the Eye, an Experimental Study in Rabbits , 2012, PloS one.

[4]  P. Nucci,et al.  A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients , 2012, TheScientificWorldJournal.

[5]  P. Lichter,et al.  Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. , 2011, Ophthalmology.

[6]  J. Fain,et al.  Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system , 2011, BMC ophthalmology.

[7]  Y. Inoue,et al.  Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells , 2010, Clinical ophthalmology.

[8]  M. Nicolela,et al.  Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. , 2010, Archives of ophthalmology.

[9]  C. Lines,et al.  Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  A. Ogundele,et al.  impact of topical bimatoprost 0 . 01 % and bimatoprost 0 . 03 % on conjunctival irritation in rabbits , 2010 .

[11]  C. Tinelli,et al.  Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination , 2010, Expert opinion on pharmacotherapy.

[12]  I. Kaur,et al.  Ocular preservatives: associated risks and newer options , 2009, Cutaneous and ocular toxicology.

[13]  T. Hamacher,et al.  Efficacy and safety levels of preserved and preservative‐free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis , 2008, Acta ophthalmologica. Supplement.

[14]  R. Gross,et al.  Duration of IOP Reduction With Travoprost BAK-free Solution , 2008, Journal of glaucoma.

[15]  R. Lewis,et al.  Travoprost 0.004% With and Without Benzalkonium Chloride: A Comparison of Safety and Efficacy , 2006, Journal of glaucoma.

[16]  Douglas R. Anderson.  Canadian glaucoma study , 2006 .

[17]  M. Parravano,et al.  Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. , 2005, American journal of ophthalmology.

[18]  C. Blondin,et al.  In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[19]  S. Whitcup,et al.  A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.